官方服务：
资源简介：
Expression of Pembrolizumab-treated tumors
应用场景：
创建时间：
2023-10-01
相关数据集
DataSheet4_A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).ZIP
It is now widely known that C-X3-C motif ligand 1 (CX3CL1) plays an essential part in the process of regulating pro-inflammatory cells migration across a wide range of inflammatory disorders, includin
NIAID Data Ecosystem00
CyTOF data of MC38 tumor-bearing mice treated with aPD-1-mEry
Splenocytes were isolated from MC38 tumor-bearing C57BL/6-hPD-1 mice receiving 2 treatments of IgG4-mEry, αPD-1, or αPD-1-mEry.
NIAID Data Ecosystem00
Genetically engineered superantigens as tolerable antitumor agents
Superantigens (SAg) are a family of bacterial and viral proteins with strong immunostimulatory properties. SAg bound to major histocompatibility complex (MHC) class II molecules activate a high freque
PubMed Central1997-03-18 更新10
Transcriptomic Profiling of Peripheral Immune Cells in a Trial of Ruxolitinib with Nivolumab for PD1 non-responsive cHL
Treatment with checkpoint inhibitors is effective in multiple cancer types. However, even in cancers with high response rates such as Hodgkin lymphoma, some patients fail to respond or relapse followi
NIAID Data Ecosystem00
